BiOMViS Srl is a Biotech Company committed to foster prophylactic and immunotherapeutic interventions in infectious diseases and cancer.
BiOMViS has proprietary technologies on the use bacterial Outer Membrane Vesicles (OMVs) as vaccine platform. OMVs are closed spheroid particles released by Gram-negative bacteria in the extracellular milieu. OMVs are …
BiOMViS Srl offers external partners highly qualified services in several research areas, including molecular and cell biology, microbial fermentation and cell culture, protein purification, immunological assays (ELISA, T cell analyses), …
BiOMViS vaccine platform is based on Outer Membrane Vesicles (OMVs) released by a non-pathogenic E. coli derivative (E. coli BL21Δ60) created by a Synthetic Biology approach. The amazing properties of …
One of the relevant features of BiOMViS’ technology is the rapidity with which OMV-based vaccine formulations can be produced and tested. Soon after the sequence and the 3D structure of …
BiOMViS has tested the potential of its OMV-based platform technology to develop a vaccine against Staphylococcus aureus. S. aureus is a human pathogen responsible for community and hospital-acquired invasive diseases. …
Tumors develop as a consequence of gene mutations that alter cellular morphology and metabolism. These mutations, that give tumors a selective growth advantage over healthy tissues, potentially represent tumors’ “Achilles’ …
Michele Tomasi, Elena Caproni, Mattia Benedet, Ilaria Zanella, Sebastiano Giorgetta, Mattia Dalsass, Enrico König, Assunta Gagliardi, Laura Fantappiè, Alvise Berti, Silvia Tamburini, Lorenzo Croia, Gabriele Di Lascio, Erika Bellini, Silvia …
 |
| BiOMViS Srl is located at the Toscana Life Sciences (TLS) Scientific Park (Siena, Italy), where it has access to fully equipped laboratories and office space and to a variety of high-tech services, including Flow cytometry, Electron Microscopy, Confocal Microscopy, Proteomic and Mass Spectrometry, Protein Purification. |
